Abstract:Objective To investigate the efficacy of sunitinib in the treatment of patients with imatinibresistant advanced gastrointestinal stromal tumor (GIST).Methods The clinical data of 45 patients with imatinib-resistant advanced GIST who received the treatment of sunitinib (37.5 mg/d) at the First Affiliated Hospital of Sun Yat-Sen University from March 2008 to June 2012 were retrospectively analyzed.The mutation of c-kit and platelet-derived growth factor receptor α (PDGFRα) was detected,and the efficacy of imatinib was assessed after the treatment for 3 months,and factors influencing the survival were analysed.The survival rate was calculated using the Kaplan-Meier method,survival analysis was done using the one-way analysis of variance,and multivariate analysis was done using the COX regression model.Results The median time of treatment with sunitinib for the 45 patients was 11.0 months (range,4-37 months).The complete remission rate,partial response rate,rate of stabilized condition and disease progression rate were 15.6％ (7/45),8.9％ (4/45),46.7％ (21/45) and 28.9％ (13/45) after the treatment with sunitinib for 3 months.All the patients with clinical (imaging) complete remission received surgery for metastatic lesions or B-ultrasound guided ablation for single liver metastasis before the treatment with sunitinib.The most common grade 3 or 4 adverse reactions of sunitinib were hand-foot syndrome and anemia.C-kit and PDGFRα mutational analysis were carried out.C-kit exon 9 mutation was detected in 9 patients,c-kit exon 11 mutation in 21 patients,and no mutation was detected in 12 patients.The median progression-free survival time was 8.0 months (range,4.1-11.9 months),and the median overall survival time was 25.0 months (range,13.4-36.6 months).The results of univariate analysis showed that the primary lesion sites and mutational status of primary lesions were factors influencing the progression-free survival and overall survival (x2=5.967,6.622 ; 7.965,8.765,P ＜ 0.05).The results of multivariate analysis showed that only the mutational status of c-kit of primary lesions was the independent factor influencing the progression-free survival and overall survival (Wald =6.540,7.205,P ＜ 0.05).The progression-free survival and overall survival of patients with c-kit exon 9 mutation and patients with no gene mutation were significantly longer than patients with c-kit exon 11 mutation (x2 =7.965,8.765,P ＜ 0.05).Conclusion Sunitinib with a dosage of 37.5 mg/d could effectively treat patients with imatinib-resistant advanced GIST.A better survival is observed in patients with c-kit exon 9 mutation or with no gene mutation when compared with patients with c-kit exon 11 mutation.

[Imatinib Mesylate STI571 Therapy for Five Patients with Advanced Gastrointestinal Stromal Tumors].

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Followed by Sunitinib Compared to Followed by Imatinib-a Multi-Center Cohort Study

Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumors

Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours (Gists)

Application of Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumor

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

Clinical Analysis of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor

Imatinib Mesylate Alone for Refractory Advanced Gastrointestinal Stromal Tumor

Influence of imatinib mesylate in the treatment of high-risk patients with gastrointestinal stromal tumors

Clinical analysis of targeted chemotherapy combined with surgical resection in locally advanced and recurrent/metastatic gastrointestinal stromal tumor

Efficacy and safety of imatinib on treatment for patients with advanced gastrointestinal stromal tumors

Molecular targeted therapy for the treatment of gastrointestinal stromal tumor

Imatinib mesylate for unresectable advanced gastrointestinal stromal tumors

P2-155: STI-571 inhibits the growth of non-small cell lung cancer cell and intensifies the cisplatin effect in vitro

Development of Sunitinib in the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

The strategy of surgical treatment and targeted therapy in gastrointestinal stromal tumors

[Efficacy of Tyrosine Kinase Inhibitor Therapy Combined with Surgical Resection in Patients with Metastatic Gastrointestinal Stromal Tumor].

[Treatment Progress of Gastrointestinal Stromal Tumor].

Efficacy and Safety of the Imatinib in the Treatment of 73 Gastrointestinal Stromal Tumors